Company: PRME
Filing Date: 2025-08-05
Form Type: 8-K
Source: 0001628280-25-037840
Chunk: 2

Company: Prime Medicine, Inc.
Filing Date: 2025-08-05
Form: 8-K
Item: Item 5.07
Chunk 2
---
Item 5.07. Submission of Matters to a Vote of Security Holders.

The Special Meeting was held on August 1, 2025. Proxies were solicited pursuant to the Company’s definitive proxy statement (the “ Proxy Statement”) filed on July 14, 2025 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of the close of business on July 9, 2025, the record date for the Special Meeting, the number of shares of Common Stock outstanding and entitled to vote at the Special Meeting was 134,496,013. The number of shares of Common Stock present in person or by remote communication, if applicable, or represented by valid proxy at the Special Meeting was 85,150,052, thus establishing a quorum for the transaction of business at the Special Meeting. Shares present virtually during the Special Meeting were considered shares of Common Stock represented in person at the Special Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company’s stockholders at the Special Meeting.

At the Special Meeting, the Company’s stockholders voted on the following matters, all of which were described in the Proxy Statement: (i) to approve the Option Repricing (the “ Option Repricing Proposal” or “ Proposal 1”) and (ii) to approve a proposal to adjourn the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of additional proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Option Repricing Proposal at the time of the Special Meeting (the “ Adjournment Proposal” or “ Proposal 2”). The final voting results are set forth below.

Proposal 1 - The Option Repricing Proposal was approved, based on the following votes: